| Bioactivity | Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer[1]. |
| Target | RON(MSPR) |
| Invitro | Narnatumab (100 nM; 24 h) 抑制 MSP 诱导的人肺癌和乳腺癌细胞系迁移[1]。Narnatumab 抑制 MSP 诱导的胰腺癌细胞有丝分裂反应[1]。Narnatumab (0.01-100 nM; 预处理 1 h) 在表达 RON 的肿瘤细胞和转染 RON 的细胞系中阻断配体诱导的受体磷酸化和下游信号分子磷酸化[1]。 |
| In Vivo | Narnatumab (2-60 mg/kg; i.p. every 3 days) 在无胸腺小鼠的非小细胞肺癌 (NSCLC) 和膀胱癌模型中显示出抗肿瘤活性[1]。Narnatumab 在小鼠体内的终末半衰期为 5.2 d，在约 140 μg/mL 的稳态血浆谷水平下实现抗肿瘤作用[1]。 Animal Model: |
| Name | Narnatumab |
| CAS | 1188275-92-4 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. LoRusso PM, et, al. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2017 Aug;35(4):442-450. |